RxDoctor Payments Data

Roy Avalos, MD

Cardiovascular Disease · Encinitas, CANPI 1154399632

Payments from drug & device makers

$18,987in general payments, 2019–2025

Across 610 payments — averaging $31.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$2K
  • Amgen$1K
  • Pfizer$1K
  • Novartis$1K
  • Merck$1K
  • AOP Health US, LLC$948
  • plus $12K from 52 others

What the payments were for

  • Travel & lodging$8194%
  • Food & beverage$18,12795%
  • Education$410%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$18,987 in reported general payments places this provider in the 80th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California

Medicare billing

Part B allowed, 2024
$783,191
Medicare patients
1,360
Services billed
6,360

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban382$471,189
XareltoRivaroxaban72$96,658
Repatha SureclickEvolocumab68$70,472
EntrestoSacubitril/Valsartan50$60,346
Praluent PenAlirocumab32$33,343
MultaqDronedarone Hcl14$27,131
NexlizetBempedoic Acid/Ezetimibe13$12,036
Propafenone Hcl168$8,267
JanuviaSitagliptin Phosphate13$7,294
Carvedilol ErCarvedilol Phosphate24$6,469
Metoprolol Succinate276$4,386
Atorvastatin Calcium389$4,239
Valsartan121$4,221
Rosuvastatin Calcium292$3,922
Prasugrel Hcl50$3,699

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$1,192$471,189382 claims
Johnson & JohnsonXarelto$389$96,65872 claims
NovartisEntresto$1,076$60,34650 claims
Sanofi-aventis U.S. LLCMultaq$458$27,13114 claims
Esperion Therapeutics, Inc.Nexlizet$717$12,03613 claims
MerckJanuvia$1,063$7,29413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,184 cardiovascular disease providers in California.

Other cardiovascular disease in Encinitas

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →